Charles Russell Speechlys produces strong performance in PitchBook rankings
Charles Russell Speechlys has produced a strong performance in the most recent PitchBook’s European private equity deals rankings.
PitchBook is a large scale data collection platform, providing reliable and comprehensive statistics spanning the full lifecycle of M&A, private equity and venture capital transactions Europe-wide, along with the firms and professionals involved.
The data collected by PitchBook allows their clients the ability to access the latest information and make ever-more informed business decisions.
PitchBook’s quarterly report provides an overview of European Private Equity transactions, with a rankings section of law firms, based upon the amount of private equity deals carried out by firms that quarter.
Charles Russell Speechlys has made a strong showing, coming out in joint fourth place as one of the few English firms mentioned alongside some key US players.
Fourth position demonstrates to PitchBook’s readership that Charles Russell Speechlys is amongst the top law firms in private equity.
Partner Malcolm MacDougall, who heads the Private Equity team, said of the ranking:
"We are delighted to be ranked so highly in the PitchBook rankings. This reflects our increasing strength and breadth in private equity. The eight private equity deals completed in the quarter span a wide range of private equity transactions, acting for private equity houses, management teams and portfolio companies. "
News & Insights
Charles Russell Speechlys double shortlisted for 2017 British Legal Awards
We are delighted to be shortlisted for Private Equity and Private Client team of the year.
Charles Russell Speechlys advises Kreos Capital on its €15 million growth capital investment
Kiadis Pharma is a clinical stage biopharmaceutical company developing innovative products to make bone marrow transplantations safer.
Charles Russell Speechlys advises Kreos Capital and Silicon Valley Bank on growth capital investment to Mereo BioPharma
Mereo BioPharma is a UK-based specialty bio-pharmaceutical company listed on the AIM market of the London Stock Exchange.
Charles Russell Speechlys shortlisted for 'Service Provider of the Year' in the Investor Allstars Awards
We are delighted to be recognised for our Venture and Growth Capital work.